Forest plot showing the meta-analysis of unadjusted relative risk estimates for response rate in NSCLC patients receiving platinum-based chemotherapy.

<p>Forest plot showing the meta-analysis of unadjusted relative risk estimates for response rate in NSCLC patients receiving platinum-based chemotherapy.</p

Summary of studies reporting ERCC1 expression and outcomes in non-small cell and small-cell lung cancer patients.

<p>RTqPCR, reverse transcriptase quantitative polymerase chain reaction; IHC, immunohistochemistry; MIC, mitomycin/ifosfamide/cisplatin; MVP, mitomycin/vinblastine/cisplatin; chemoRT, chemoradiotherapy; NS, not stated;</p><p>*, number of patients assessable for ERCC1 expression and overall survival;</p>ƒ<p>, one patient received adjuvant chemoradiotherapy;</p>⌋<p>, % high ERCC1 expression overall (data not stated for subgroups separately).</p

Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for OS in NSCLC patients not treated with chemotherapy.

<p>Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for OS in NSCLC patients not treated with chemotherapy.</p

Meta-analysis results.

<p>OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval.</p

Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for OS in NSCLC patients receiving platinum-based chemotherapy.

<p>Forest plot showing the meta-analysis of unadjusted hazard ratio estimates for OS in NSCLC patients receiving platinum-based chemotherapy.</p

Results of survival analyses by individual study.

<p>HRs and associated 95% CIs are given as quoted unless stated otherwise, (—) indicates not assessed;</p><p>*estimated result from data presented in paper using methods of Palmer et al. (REF);</p><p>HR, hazard ratio; CI, confidence interval; LS, limited stage; ES, extensive stage.</p

Table 1: Primary sites of extrapulmonary small cell carcinomas identified

Primary sites of EPSCC were grouped by organ system to aid analysi

Figure 2b: Kaplan–Meier plot for overall survival (OS) for all patients, grouped by treatment intent.

Kaplan–Meier plot for overall survival (OS) for all patients, grouped by treatment intent

Figure 2a: Kaplan–Meier plot for overall survival (OS) for all patients, grouped by disease stage at diagnosis.

Kaplan–Meier plot for overall survival (OS) for all patients, grouped by disease stage at diagnosis

Table 2A: : Univariate Cox regression analysis for overall survival

Univariate Cox regression analysis for overall survival for patients with EPSCC